Attached files
| file | filename |
|---|---|
| 8-K - SYNERGETICS USA 8-K 10-6-2011 - SYNERGETICS USA INC | form8k.htm |
| EX-99.1 - EXHIBIT 99.1 - SYNERGETICS USA INC | ex99_1.htm |
OPHTHALMOLOGY
NEUROSURGERY
Craig-Hallum Capital Group 2nd Annual Alpha Select Conference
New York, New York
October 6, 2011
Investor Presentation
QUALITY. PERFORMANCE. INNOVATION.
Certain statements made in this presentation are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. Among
other, statements concerning management’s expectations of future financial
results, potential business, acquisitions, government agency approvals,
additional indications and therapeutic applications for medical devices, as
well as their outcomes, clinical efficacy and potential markets are forward
looking. Forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from predicted results. For a
discussion of such risks and uncertainties, please refer to the information set
forth under “Risk Factors” included in Synergetics USA, Inc.’s Annual Report
on Form 10-K for the year ended July 31, 2010 and information contained in
subsequent filings with the Securities and Exchange Commission. These
forward looking statements are made based upon our current expectations
and we undertake no duty to update information provided in this
presentation.
meaning of the Private Securities Litigation Reform Act of 1995. Among
other, statements concerning management’s expectations of future financial
results, potential business, acquisitions, government agency approvals,
additional indications and therapeutic applications for medical devices, as
well as their outcomes, clinical efficacy and potential markets are forward
looking. Forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from predicted results. For a
discussion of such risks and uncertainties, please refer to the information set
forth under “Risk Factors” included in Synergetics USA, Inc.’s Annual Report
on Form 10-K for the year ended July 31, 2010 and information contained in
subsequent filings with the Securities and Exchange Commission. These
forward looking statements are made based upon our current expectations
and we undertake no duty to update information provided in this
presentation.
2
• Synergetics is a medical device company focused in
the ophthalmology and neurosurgery market
the ophthalmology and neurosurgery market
• Synergetics USA, Inc. was formed through a reverse
merger of Synergetics, Inc. and Valley Forge
Scientific in 2005
merger of Synergetics, Inc. and Valley Forge
Scientific in 2005
• Synergetics was founded in 1991 and Valley Forge
was founded in 1980 and became a publicly-held
company in November 1989
was founded in 1980 and became a publicly-held
company in November 1989
• Synergetics USA, Inc. (NASDAQ: SURG)
• Corporate Headquarters: O’Fallon, MO
• Manufacturing Facilities: O’Fallon, MO and
King of Prussia, PA
King of Prussia, PA
• Shares Outstanding: 24.97mm
• 52 Week Range: $2.70 - $6.01
• Market Cap.: $130.82mm
• June 2011 added to Russell 2000 & 3000 Indexes
3
4
§ Major Events:
§ Alcon Settlement
§ Neurosurgery Transition
§ Project Restore
5
§ Drive operational efficiencies to improve the platform’s
profitability
profitability
§ Neurosurgery - Generate Cash
§ Ophthalmology: Strategic Growth
§ Sales Force Productivity
6
Markets
7
2011 Anterior (Cataract) and
Posterior (Retinal) Markets Compared
8
9
§ Anti-VEGF Therapies (i.e. Lucentis)
§ Long Term Drug Delivery Implants
§ Artificial Vision
§ Microplasmin Vitreous Disinsertion
§ Site of Service Migration, e.g. ASC, Office
10
Product Review
11
Ophthalmology Products
12
DDMS
Quantel Laser
Directional Laser Probes
Endoilluminator - Awh Chandelier
Photon II
13
The OMNI is the most innovative
and user-friendly ultrasonic
aspirator available. In addition to
the soft tissue removal
capabilities common, it
effectively addresses dense,
fibrotic lesions, and pioneers the
fine dissection of bone
traditionally performed with
rotating drills.
and user-friendly ultrasonic
aspirator available. In addition to
the soft tissue removal
capabilities common, it
effectively addresses dense,
fibrotic lesions, and pioneers the
fine dissection of bone
traditionally performed with
rotating drills.
The OMNI
The Disposable Spetzler-Malis “Yellow”
bipolar forceps offer surgeons brand-
new, high-polished tips for guaranteed
non-stick performance.
bipolar forceps offer surgeons brand-
new, high-polished tips for guaranteed
non-stick performance.
Disposable
Bipolar Forceps
Our next generation Malis® Bipolar
Generator. Dual-waveform
technology provides delicate and
efficient cutting and coagulation
control at even lower power
settings, further reducing thermal
spread and collateral tissue
damage.
Generator. Dual-waveform
technology provides delicate and
efficient cutting and coagulation
control at even lower power
settings, further reducing thermal
spread and collateral tissue
damage.
14
Stryker
Codman
CMC V
Codman
Synergy
Synergy
Stryker Lesion
Generator
Generator
15
16
17
Financials
18
§ Sales were up 21% for the fourth quarter ended July 31, 2011
with disposables sales up 23.0% and capital sales down
2.3%.
with disposables sales up 23.0% and capital sales down
2.3%.
§ Net income and earnings per share doubles.
§ Total interest bearing debt decreased $3.0 million from
FYE 2010 to approximately $1.1 million bringing our leverage
down to 2.0%.
FYE 2010 to approximately $1.1 million bringing our leverage
down to 2.0%.
§ Post Alcon transaction (including payment of taxes),
Company has $18.4 million of cash on its balance sheet and
has significantly reduced its debt.
Company has $18.4 million of cash on its balance sheet and
has significantly reduced its debt.
19
§ Improved stability of the platform
§ Reinvigorating sales growth
§ Unique, technically proficient worldwide distribution
capability
capability
§ Opportunity to create “Fast Follower” that will be viewed
as an attractive entry vehicle to ophthalmology
as an attractive entry vehicle to ophthalmology
20
§ David M. Hable - President, CEO
Over 30 years of progressive responsibility in sales, marketing, new business development and general
management in the medical device industry.
management in the medical device industry.
§ Pamela Boone - Executive Vice President, CFO
Previously served as CFO, VP, and Corporate Controller for Maverick Tube Corporation. 25 years of
financial expertise.
financial expertise.
§ Kurt Gampp - Executive Vice President, COO
Co-founded Synergetics, Inc. Over 30 years of microsurgical instrument making experience.
§ Jerry Malis, M.D. - Executive Vice President, CSO
Served as President, CEO, & Chairman of Valley Forge. Over 40 years of industry experience. Published
over 50 articles in the biological science, electronics and engineering fields. Issued ten U.S. patents.
over 50 articles in the biological science, electronics and engineering fields. Issued ten U.S. patents.
§ Jason Stroisch - Vice President, Marketing
Over 15 years experience in the medical device industry covering engineering, international sales and
marketing management roles.
marketing management roles.
§ Michael Fanning - Vice President, Sales
Over 20 years in sales and management roles, working in service, medical device, and manufacturing
sectors.
sectors.
21
OPHTHALMOLOGY
NEUROSURGERY
Craig-Hallum Capital Group 2nd Annual Alpha Select Conference
New York, New York
October 6, 2011
Investor Presentation
QUALITY. PERFORMANCE. INNOVATION.
3845 Corporate Centre Drive
O’Fallon, MO 63368
(636) 939-5100
www.synergeticsusa.com